OLMA vs. PAHC, MLYS, CALT, KRRO, VERV, ALT, CVAC, NUVB, GHRS, and PHAT
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Phibro Animal Health (PAHC), Mineralys Therapeutics (MLYS), Calliditas Therapeutics AB (publ) (CALT), Korro Bio (KRRO), Verve Therapeutics (VERV), Altimmune (ALT), CureVac (CVAC), Nuvation Bio (NUVB), GH Research (GHRS), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical preparations" industry.
Olema Pharmaceuticals (NASDAQ:OLMA) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
Phibro Animal Health received 283 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. Likewise, 60.04% of users gave Phibro Animal Health an outperform vote while only 59.46% of users gave Olema Pharmaceuticals an outperform vote.
Olema Pharmaceuticals currently has a consensus target price of $21.43, suggesting a potential upside of 115.36%. Phibro Animal Health has a consensus target price of $15.33, suggesting a potential upside of 20.45%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Olema Pharmaceuticals is more favorable than Phibro Animal Health.
91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 23.5% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Olema Pharmaceuticals has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.
In the previous week, Phibro Animal Health had 6 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for Phibro Animal Health and 0 mentions for Olema Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.83 beat Olema Pharmaceuticals' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.
Phibro Animal Health has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Phibro Animal Health has a net margin of 1.51% compared to Olema Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 16.67% beat Olema Pharmaceuticals' return on equity.
Summary
Phibro Animal Health beats Olema Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
